QIAGEN NV (QGEN)

36.20
0.23 0.63
NASDAQ : Health Technology
Prev Close 36.43
Open 36.44
Day Low/High 36.11 / 36.46
52 Wk Low/High 30.20 / 37.61
Volume 301.40K
Avg Volume 849.90K
Exchange NASDAQ
Shares Outstanding 226.56M
Market Cap 8.27B
EPS 0.20
P/E Ratio 214.82
Div & Yield N.A. (N.A)

Latest News

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMGN, CIG.C, COTV, CTRE, GMS, HPT, IAG, NFEC, QGEN, SCVL, THR, TPHS, USFD, UVV Downgrades: BKE, IGT, TSLX, VRX Initiations: MGEN Read on to get TheStreet Quant Ratings' detailed report:

QIAGEN Welcomes WHO's Essential Diagnostics List Which Includes QuantiFERON-TB Gold

QIAGEN Welcomes WHO's Essential Diagnostics List Which Includes QuantiFERON-TB Gold

QIAGEN today welcomed the First Edition of the World Health Organization's (WHO) Essential Diagnostics List, which endorses the use of interferon gamma release assays (IGRAs) for the diagnosis of latent TB infection.

QIAGEN Reports Results For First Quarter 2018

QIAGEN Reports Results For First Quarter 2018

QIAGEN N.V.

QIAGEN Announces FDA Approval Of PartoSureTM

QIAGEN Announces FDA Approval Of PartoSureTM

QIAGEN N.V.

Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections

Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections

Watch for these upstart names to topple some big-caps going forward.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: TWNK, VIRT Downgrades: AKAM, APLE, ATVI, BHE, BRFS, CAT, CCK, CDR, CUB, DIOD, DLHC, EXPE, GRA, GT, HCN, JNPR, NWSA, QGEN, REG, SEE, SUM, SXT, TRMB, UHAL, UNVR Initiations: ICHR Read on to get TheStreet Quant Ratings' detailed report:

QIAGEN Enters Into Agreement To Acquire STAT-Dx, Plans To Launch A Next-Generation, Fully Integrated Multiplex Platform For Syndromic Disease Testing

QIAGEN Enters Into Agreement To Acquire STAT-Dx, Plans To Launch A Next-Generation, Fully Integrated Multiplex Platform For Syndromic Disease Testing

New system launch planned for second half of 2018 with two CE-IVD molecular diagnostics, U.S. launch planned for 2019 and broad pipeline in development

QIAGEN Receives FDA Clearance For First-Ever JAK2 Test For Use In Diagnosis Of Additional Myeloproliferative Neoplasms

QIAGEN Receives FDA Clearance For First-Ever JAK2 Test For Use In Diagnosis Of Additional Myeloproliferative Neoplasms

Expanded use of ipsogen test provides diagnostic testing needs for all myeloproliferative neoplasms in line with the latest WHO guidelines

QIAGEN Receives FDA Approval To Expand Use Of EGFR Test In Lung Cancer

QIAGEN Receives FDA Approval To Expand Use Of EGFR Test In Lung Cancer

Extended labeling claim adds detection of three additional gene mutations to provide the most comprehensive mutation panel for GILOTRIF®

Interesting QGEN Put And Call Options For August 2018

Interesting QGEN Put And Call Options For August 2018

Investors in Qiagen NV saw new options begin trading this week, for the August 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Biomillenia Leverages QIAGEN Bioinformatics In Microbiome-on-a-Chip Discovery Of Unculturable Microbes

Biomillenia Leverages QIAGEN Bioinformatics In Microbiome-on-a-Chip Discovery Of Unculturable Microbes

Biomillenia, the developer of Smart Microbes™, announced today a collaboration with QIAGEN N.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMZN, CKH, GDDY, PRSC, QGEN, SHLM, VRX Downgrades: BRG, CZWI, FBP, HAIN, LNCE, PIH, TAIT, TPR, TTWO Initiations: ASIX, CWH Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AGCO, CAL, CRS, CY, EXPE, JCI, LLNW, MITL, UPS Downgrades: AHL, BMS, EHTH, ESND, MLCO, QGEN, VGR Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EFII, ENBL, NNBR, PHI, QGEN, SYX, TIER, WEX, WILC Downgrades: ADES, AEGN, ARES, CVLT, ECOM, PSX, WES Initiations: WATT Read on to get TheStreet Quant Ratings' detailed report:

Bristol-Myers Squibb And QIAGEN Sign Agreement For Use Of NGS Technology To Develop Gene Expression Profiles For Immuno-Oncology Therapies

Bristol-Myers Squibb Company (NYSE:BMY) and QIAGEN (NASDAQ:QGEN; Frankfurt Prime Standard:QIA) have signed an agreement to explore the use of next-generation sequencing (NGS) technology to develop gene expression...

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AAN, CR, CVLT, CWCO, GPRK, KMB, MDLZ, MVC, OPB, POL, PW, RMBS, SNY Downgrades: ACOR, AKR, FCCY, NRZ, QGEN, SSY, SWFT, TBBK, WRI Initiations: UA Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: B (Buy)